Phase 1 N=61 Phase I Trial of BI 836845 for Various Solid Cancer
Neoplasms
Primary: Part 1: Maximum Tolerated Dose (MTD) of BI 836845 During the First Treatment Course of the Dose Escalation Phase. — 1000 milligram (mg)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=900 Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits
Glaucoma · Diabetic Retinopathy · Refractive Errors
Primary: Percentage of Participants That Adhere to Referral Appointment — 80; 92 Participants
Phase 1 N=11 ABEMA Alone or in COMBO With MK-6482
Clear Cell Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) in Abemaciclib Arm (Arm 1) — 0 Participants
Phase 1 N=40 A Phase 1a Study of PMN310 In Healthy Volunteers
Healthy Participants
Primary: Incidence of Treatment Emergent Adverse Events — 2; 2; 0; 3 participants
N/A N=19 Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Kidney Cancer · Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma
Primary: Initial Objective Response- First Participation — 5; 1; 7; 4 Participants
N/A N=24 Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Cure Rate — 18 Participants
N/A N=23 Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate — 9 Participants
Phase 2 N=16 IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer · Head and Neck Carcinoma
Primary: Participants Experiencing Adverse Events — 10 Participants
N/A N=60 Epidural Anesthesia for Transurethral Resection of The Prostate
Epidural Catheter · Epidural Analgesia · Geriatric Cardiology
Primary: Time to Reach Sensory Block at T10 — 15.25; 10.50; 11.25 Minutes — p=0.05
Phase 3 N=169 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
Bronchiolitis Obliterans · Chronic Rejection of Lung Transplant · Lung Transplant Rejection
Primary: Mean Change in FEV1 (Liters) From Baseline to Week 48 — -0.096; -0.067 Liters — p=0.6639
N/A N=139 A Patient-facing Tool to Reduce Opioid-Psychotropic Polypharmacy in People Living With Dementia (PLWD)
Polypharmacy · Dementia
Primary: Change in Total Standardized Daily Dosage (TSDD) of CNS-Active Medications From Baseline to 4 Months, as Measured in the EHR — 9.0; 9.0; -1.3; -1.6 doses per day
Phase 2 N=103 Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
Chronic Hepatitis B
Primary: Percentage of Participants Who Achieved Functional Cure — 2.4; 2.5; 0.0 percentage of participants
Phase 2 N=35 Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia · Stage III Chronic Lymphocytic Leukemia
Primary: Rate of Confirmed MRD-negative Response — 0 proportion of patients
Phase 4 N=54,100 Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
Malaria · Malaria Vaccines
Primary: Number of Participants Infected With Plasmodium Falciparum (P. Falciparum) by World Health Organisation (WHO) Age Group — 98; 148; 82; 46 Participants
Phase 2 N=111 Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
Neuroendocrine Tumors
Primary: Best Response Rate by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Upon Central Radiologic Assessment — 0; 0; 23; 9 Participants